137 related articles for article (PubMed ID: 4150441)
21. Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (Azulfidine).
Franklin JL; Rosenberg HH
Gastroenterology; 1973 Apr; 64(4):517-25. PubMed ID: 4144775
[No Abstract] [Full Text] [Related]
22. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
[TBL] [Abstract][Full Text] [Related]
23. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
Sharp ME; Wallace SM; Hindmarsh KW; Brown MA
Eur J Clin Pharmacol; 1981; 21(3):243-50. PubMed ID: 6119205
[No Abstract] [Full Text] [Related]
24. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.
Lauritsen K; Hansen J; Ryde M; Rask-Madsen J
Gastroenterology; 1984 Jun; 86(6):1496-500. PubMed ID: 6143704
[TBL] [Abstract][Full Text] [Related]
25. Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine.
Hansson KA
Acta Pharm Suec; 1973 May; 10(2):153-5. PubMed ID: 4146997
[No Abstract] [Full Text] [Related]
26. 1986 Stuart distinguished lecture. The "natural history" of inflammatory bowel disease and therapeutic decisions.
Janowitz HD
Am J Gastroenterol; 1987 Jun; 82(6):498-503. PubMed ID: 2883884
[No Abstract] [Full Text] [Related]
27. Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis?
Fischer C; Klotz U
Ther Drug Monit; 1980; 2(2):153-8. PubMed ID: 6132473
[No Abstract] [Full Text] [Related]
28. [Our experience in the treatment of ulcerative colitis and Crohn disease of the colon].
Pesce GL; Zanetti PP
Minerva Chir; 1984 Apr; 39(7):531-3. PubMed ID: 6472666
[No Abstract] [Full Text] [Related]
29. The fulminating case of ulcerative colitis and Crohn's disease.
Aylett S
Proc R Soc Med; 1970; 63 Suppl(Suppl 1):75-6. PubMed ID: 5525513
[No Abstract] [Full Text] [Related]
30. Pulmonary function in patients with inflammatory bowel disease.
Eade OE; Smith CL; Alexander JR; Whorwell PJ
Am J Gastroenterol; 1980 Feb; 73(2):154-6. PubMed ID: 6104919
[TBL] [Abstract][Full Text] [Related]
31. Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy.
Gorbach SL; Nahas L; Plaut AG; Weinstein L; Patterson JF; Levitan R
Gastroenterology; 1968 Apr; 54(4):575-87. PubMed ID: 4385122
[No Abstract] [Full Text] [Related]
32. [Pharmacological bases of therapy with 5-ASA].
Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
[No Abstract] [Full Text] [Related]
33. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.
Das KM; Eastwood MA; McManus JP; Sircus W
Gut; 1973 Aug; 14(8):631-41. PubMed ID: 4147555
[TBL] [Abstract][Full Text] [Related]
34. Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats.
Das KM; Chowdhury JR; Zapp B; Fara JW
Gastroenterology; 1979 Aug; 77(2):280-4. PubMed ID: 36326
[TBL] [Abstract][Full Text] [Related]
35. Two first degree relatives with dilatation of the colon due to Crohn's disease.
Mallinson CN; Candy JC; Cowan R; Prior A
Guys Hosp Rep; 1973; 122(3-4):211-20. PubMed ID: 4376100
[No Abstract] [Full Text] [Related]
36. [Ulcerative rectocolitis: current clinical and therapeutic concepts].
Larizza D; Boni R
Clin Ter; 1982 Nov; 103(3):303-18. PubMed ID: 6129939
[No Abstract] [Full Text] [Related]
37. [Current therapeutic possibilities in chronic inflammatory intestinal diseases].
Schölmerich J
Praxis (Bern 1994); 1995 Jan; 84(2):29-33. PubMed ID: 7839043
[TBL] [Abstract][Full Text] [Related]
38. [Chronic idiopathic enterocolitis and pregnancy. Reciprocal repercussions and treatment].
Cléandre D; Dufour P; Tiberghien B; Bernardi C; Vinatier D; Monnier JC
J Gynecol Obstet Biol Reprod (Paris); 1993; 22(1):59-65. PubMed ID: 8096531
[TBL] [Abstract][Full Text] [Related]
39. Selected individual therapeutic problems in inflammatory bowel disease.
Kirsner JB; Deutsch S; Hanauer SB
Am J Gastroenterol; 1984 May; 79(5):368-75. PubMed ID: 6144267
[No Abstract] [Full Text] [Related]
40. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Nakajima H; Munakata A; Yoshida Y
J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
